Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: Effect of FK506, an inhibitor of T cell activation

Inflammation Research

Volumn 53, Issue 9, 2004, Pages 469-474

  Magari, K ^a   Miyata, S ^a   Ohkubo, Y ^a   Mutoh, S ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Collagen induced arthritis; FK506; Interleukin 1 ; Interleukin 6; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

COLLAGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEOGLYCAN; TACROLIMUS; TISSUE EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE; CARTILAGE DEGENERATION; CHEMICAL COMPOSITION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR HEAD; NONHUMAN; PAW EDEMA; PROTEIN FUNCTION; RAT; T LYMPHOCYTE ACTIVATION; TISSUE LEVEL; UPREGULATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; CYTOKINES; FEMALE; HINDLIMB; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; RATS; RATS, INBRED LEW; TACROLIMUS; TREATMENT OUTCOME; UP-REGULATION;

EID: 6044261211     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1284-y     Document Type: Article

References (38)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
2. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 729-35.
3. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51: 207-29.
4. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001; 19: 163-96.
5. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 857-68.
6. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 11-8.
7. Klareskog L, Holmdahl R, Larsson E, Wigzell H. Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol 1983; 51: 117-25.
8. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
9. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648-59.
10. van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 237-43.
11. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Effiicacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
12. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41; 2117-21.
13. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001; 107: 1519-27.
14. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999; 42: 1109-18.
15. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 507-12.
16. Palmblad K, Erlandsson-Harris H, Tracey KJ, Andersson U. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis. A therapeutic study using a macrophage-deactivating compound. Am J Pathol 2001; 158: 491-500.
17. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987; 40: 1256-65.
18. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718-26.
19. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-5.
20. Karran EH, Young TJ, Markwell RE, Harper GP. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Ann Rheum Dis 1995; 54: 662-9.
21. Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y. The oral dosage form of FK-506. Transplant Proc 1987;19 Suppl 6: 17-22.
22. Billingham MEJ. Models of arthritis and the search for anti-arthritic drugs. Pharmac Ther 1983; 21: 389-428.
23. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5; 298-304.
24. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Haines III GK et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 1266-77.
25. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and Methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003; 30: 2193-200.
26. Magari K, Nishigaki F, Sasakawa T, Ogawa T, Miyata S, Ohkubo Y, et al. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm Res 2003; 52: 524-529.
27. Nishikawa N, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670-81.
28. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003; 5: R122-31.
29. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988; 46: 82-90.
30. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002; 46: 2020-8.
31. Magari K, Miyata S, Ohkubo Y, Mutoh S, Goto T. Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 2003; 139: 927-34.
32. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S et al. FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 2000; 130: 1655-63.
33. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 2001; 1: 749-57.
34. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene. Arthritis Rheum 1997; 40: 1662-9.
35. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
36. Joosten LAB, Helsen MMA, Saxne T, van de Loo FAJ, Heinegård D, van den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-55.
37. Ridderstad A, Abedi-Valugerdi M, Moller E. Cytokines in rheumatoid arthritis. Ann Med 1991; 23: 219-23.
38. Manolagas SC. Role of cytokines in bone resorption. Bone 1995; 17 Suppl 2: 63S-7S.